

## ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS



PHM025D  
March 2016

Neha Maliwal  
*Project Analyst*

ISBN: 1-62296-252-4



**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
SCOPE OF REPORT	3
INTENDED AUDIENCE	3
RESEARCH METHODOLOGY	4
ANALYST'S CREDENTIALS	5
RELATED BCC RESEARCH REPORTS	5
BCC RESEARCH WEBSITE	5
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL ANTIBIOTICS MARKET BY CLASS, 2015 AND 2020 (\$ MILLIONS)</i>	8
CHAPTER 3 MARKET OVERVIEW	10
INTRODUCTION	10
BACTERIA	10
<i>TABLE 1 DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA</i>	11
GRAM-POSITIVE BACTERIA	12
GRAM-NEGATIVE BACTERIA	12
Mycobacterium	13
<i>TABLE 2 CLASSIFICATION OF BACTERIA BY SHAPE</i>	13
BACTERIAL INFECTIONS	14
RESPIRATORY TRACT INFECTIONS	15
Upper Respiratory Tract Infection	15
<i>TABLE 3 PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS</i>	15
<i>TABLE 4 INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)</i>	17
Lower Respiratory Tract Infection	17
PNEUMONIA	17
<i>TABLE 5 COMMON CAUSATIVE MICROBES OF COMMUNITY AND HOSPITAL-ACQUIRED PNEUMONIA</i>	18
Community-acquired Pneumonia	18
Hospital-acquired Pneumonia	18
<i>TABLE 6 PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING BACTERIAL PNEUMONIA</i>	19
<i>TABLE 7 INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010 (NUMBER/%)</i>	19
TUBERCULOSIS	20
URINARY TRACT INFECTIONS (UTI)	20
<i>TABLE 8 INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)</i>	21
SKIN AND SKIN STRUCTURE INFECTIONS	21

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 9 INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)</i>	22
Cellulitis and Erysipelas	22
Folliculitis	22
Impetigo and Ecthyma	23
Abscesses	23
Carbuncles and Furuncles	23
GYNECOLOGICAL INFECTIONS	23
<i>TABLE 10 INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)</i>	24
DEFINITION OF ANTIBIOTIC	24
CLASSIFICATION OF ANTIBIOTICS	24
<i>FIGURE 1 CLASSIFICATION OF ANTIBIOTICS</i>	25
HISTORY OF ANTIBIOTICS AND CURRENT STATUS	25
PRE-ANTIBIOTIC ERA	25
ANTIBIOTIC ERA	26
<i>TABLE 11 U.S. LIFE EXPECTANCY AT BIRTH, 1920-2013 (YEARS)</i>	26
<i>TABLE 12 ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES</i>	27
ANTIBIOTIC-RESISTANT BACTERIA	28
MECHANISM OF RESISTANCE	29
<i>TABLE 13 ANTIBIOTICS: MODE OF ACTION</i>	30
Mechanisms of Antimicrobial Resistance	30
<i>TABLE 14 ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050 (NUMBER)</i>	31
Methods for the Dissemination of Antimicrobial Resistance Genes	32
Resistance to B-Lactam Antibiotics	32
Tetracycline Resistance	32
Chloramphenicol Resistance	32
Aminoglycoside Resistance	33
Quinolone Resistance	33
Macrolide, Lincosamide, and Streptogramin (MLS) Resistance	33
Glycopeptide Resistance	33
Sulfonamides and Trimethoprim Resistance	34
Multidrug Resistance	34
<i>TABLE 15 TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE</i>	34
<i>TABLE 16 CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA</i>	35
EMERGENCE OF POST-ANTIBIOTIC ERA	36
<i>TABLE 17 BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE</i>	37
<i>FIGURE 2 CDC LIST OF HIGHLY CONCERNING BACTERIA, ACCORDING TO THREAT LEVEL</i>	37
<i>TABLE 18 ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA BY REGION</i>	38
Limitation of Antibiotics	39
Some Antibiotics are Active against Only Certain Kinds of Bacteria	39
Some Bacteria are Virulent and Can Kill Quickly	40
Some Bacteria Grow in Biofilms that cannot be Easily Penetrated by Antibiotics	40

<b>TOPIC</b>	<b>PAGE NO.</b>
DRIVERS RESTRAINTS AND OPPORTUNITIES	40
DRIVERS	40
Growth of the Global Pharmaceutical Market Driven by Antibiotics	40
Aging Population Propels the Growth of the Antibiotics Market	41
<i>FIGURE 3 INCREASE IN AGING POPULATION, 2011 AND 2050</i>	41
Public-Private Partnerships Encourage Antibiotic Development	42
Increasing Prevalence of Hospital-Acquired Infections Triggers Market Growth	42
RESTRAINTS	43
Antibiotic Resistance	43
Declining R&D Investment Poses Long-Term Barrier to Market Growth	44
Genericization of Antibiotics Restrains Market Growth	44
OPPORTUNITIES	44
Market Expansion into Emerging Countries	44
Multidrug-Resistant Pathogens Provide an Opportunity to Develop Novel Antibacterial Agents	45
BURNING ISSUE	46
New Antibiotic Discovered From Soil	46
MARKET SHARES OF KEY COMPANIES	46
<i>FIGURE 4 GLOBAL MARKET SHARES FOR ANTIBIOTIC COMPANIES, 2014 (%)</i>	46
VALUE CHAIN OF ANTIBIOTICS	48
CHINA IS A BECOMING A CENTER FOR MICROBIAL THREATS	49
REGULATORY ISSUES	50
FDA AND INTERNATIONAL REGULATORY AGENCIES	50
RECENT REGULATORY REFORMS	51
KETEK CASE STUDY	51
KEY TRENDS AFFECTING THE MARKET	52
NEVER EVENTS	52
Impact on the Use of Antibiotics	53
FUNDING FOR NEW ANTIBIOTICS	53
United States	53
Infectious Diseases Society of America	53
NIH Funding	54
Public-Private Partnerships	54
Europe	55
Innovative Medicines Initiative	55
EMERGING DRUGS WITH NOVEL MECHANISMS OF ACTION	56
PharmaSea Project	56
Combination of Different Antibiotics	56
Others	57
CHAPTER 4 ANTIBIOTIC RESEARCH AND DEVELOPMENT	59
REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH	59
<i>FIGURE 5 REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH</i>	60
LOW RETURN ON INVESTMENT	60
STRICT REGULATORY ENVIRONMENT	61
SCIENTIFIC CHALLENGES	62
STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH	62

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 6 STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH</i>	62
PUSH STRATEGIES	63
Increasing Access to Research	63
Increasing the Number of Scientific Personnel	64
Direct Funding of Research	64
Translational Research	66
Tax Incentives	66
Product Development Partnerships	67
PULL STRATEGIES	67
Monetary Awards	67
Advance Market Commitments	68
Legal and Regulatory Initiatives	69
Clinical Trials	69
Accelerated Regulatory Review	70
Intellectual Property Rights Strategies	70
Increasing the Term of IP Protection and Data Exclusivity	71
Wildcard Patent Extension	71
Patent Buyouts	72
Pricing and Reimbursement	72
Other Legal/Regulatory Strategies	72
COMBINED PULL AND PUSH INCENTIVES	73
ORPHAN DRUG STATUS	73
<i>TABLE 19 COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS</i>	73
Delinkage of Antibiotics	74
<i>TABLE 20 LIST OF DELINKAGE MODELS</i>	75
<i>TABLE 21 LIST OF HYBRID MODELS</i>	77
CHAPTER 5 ANTIBIOTICS MARKET BY TYPE	80
MARKET SIZE ESTIMATION	80
MARKET SHARE ESTIMATION	80
GLOBAL ANTIBIOTICS MARKET BY CLASS	81
<i>TABLE 22 GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 (\$ MILLIONS)</i>	81
<i>TABLE 23 GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	81
<i>FIGURE 7 ANTIBIOTICS BY CLASS</i>	81
BETA-LACTAM ANTIBIOTICS	82
<i>TABLE 24 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	84
<i>TABLE 25 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	84
Extended Spectrum Beta-Lactamase	84
Metallo-Beta-Lactamases	85
<i>FIGURE 8 TYPES OF BETA-LACTAM ANTIBIOTICS</i>	85
Penicillins	85
<i>TABLE 26 GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	86
Types of Penicillin	87
<i>TABLE 27 TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE</i>	88

<b>TOPIC</b>	<b>PAGE NO.</b>
Cephalosporins	88
Side Effects	89
<i>TABLE 28 GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	89
Teflaro Driving the Cephalosporin Market	90
Generations of Cephalosporins	90
<i>TABLE 29 GENERATIONS OF CEPHALOSPORIN</i>	90
First-Generation Cephalosporins	91
<i>TABLE 30 LIST OF FIRST-GENERATION CEPHALOSPORINS</i>	91
Second-Generation Cephalosporins	92
<i>TABLE 31 LIST OF SECOND-GENERATION CEPHALOSPORINS</i>	92
Third-Generation Cephalosporins	92
Antipseudomonal Cephalosporins	93
<i>TABLE 32 LIST OF THIRD-GENERATION CEPHALOSPORINS</i>	93
Fourth-Generation Cephalosporins	94
<i>TABLE 33 LIST OF FOURTH-GENERATION CEPHALOSPORINS</i>	94
Fifth-Generation Cephalosporins	94
<i>TABLE 34 LIST OF FIFTH-GENERATION CEPHALOSPORINS</i>	95
Carbapenems	95
<i>TABLE 35 GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	96
<i>TABLE 36 TYPES OF CARBAPENEMS</i>	96
QUINOLONES AND FLUOROQUINOLONES	96
<i>TABLE 37 DEVELOPMENT HISTORY OF FLUOROQUINOLONES</i>	98
<i>TABLE 38 GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH 2020 (\$ MILLIONS)</i>	98
<i>TABLE 39 GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	99
Generations of Quinolones	99
First-Generation Quinolones	99
Second-Generation Fluoroquinolones	99
<i>TABLE 40 GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	100
Third-Generation Fluoroquinolones	100
<i>TABLE 41 GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	101
Levofloxacin: A Major Driver of the Market for Third-Generation Fluoroquinolones	101
Fourth-Generation Fluoroquinolones	101
<i>TABLE 42 GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	102
<i>TABLE 43 TYPES OF QUINOLONES</i>	102
TETRACYCLINE	103
<i>TABLE 44 GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	104
<i>TABLE 45 TYPES OF TETRACYCLINE</i>	104
MACROLIDES	105
<i>TABLE 46 GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	106

<b>TOPIC</b>	<b>PAGE NO.</b>
Ketolides	106
Ketek	107
<i>TABLE 47 TYPES OF MACROLIDES/KETOLIDES</i>	107
OTHER ANTIBIOTICS	107
Pseudomonas Aeruginosa	107
<i>TABLE 48 GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020 (\$ MILLIONS)</i>	108
CHAPTER 6 VETERINARY ANTIBIOTICS MARKET	111
INTRODUCTION	111
<i>TABLE 49 DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS</i>	111
<i>TABLE 50 GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)</i>	112
VETERINARY APPLICATIONS	112
FEED APPLICATION	112
FDA to Phase out Antibiotics from Food Production	113
THERAPEUTIC APPLICATIONS	114
<i>TABLE 51 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2020 (\$ MILLIONS)</i>	114
<i>TABLE 52 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2020 (\$ MILLIONS)</i>	115
OTHER APPLICATIONS	115
CHAPTER 7 COMPANY PROFILES	118
ASTRAZENECA	118
FINANCIALS	118
<i>TABLE 53 ASTRAZENECA REVENUES AND R &amp; D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)</i>	118
DEVELOPMENTS	119
<i>TABLE 54 ASTRAZENECA DEVELOPMENTS</i>	119
BAYER HEALTHCARE AG	120
FINANCIALS	120
<i>TABLE 55 BAYER REVENUES AND R &amp; D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)</i>	120
DEVELOPMENTS	120
CUBIST PHARMACEUTICALS	120
DEVELOPMENTS	121
<i>TABLE 56 CUBIST PHARMACEUTICAL DEVELOPMENTS</i>	121
GLAXOSMITHKLINE	122
FINANCIALS	122
<i>TABLE 57 GSK REVENUES AND R &amp; D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)</i>	122
DEVELOPMENTS	123
<i>TABLE 58 GSK DEVELOPMENTS</i>	123
JOHNSON & JOHNSON	124
FINANCIALS	124
<i>TABLE 59 JOHNSON &amp; JOHNSON REVENUES AND R &amp; D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)</i>	124
DEVELOPMENTS	125
<i>TABLE 60 JOHNSON &amp; JOHNSON DEVELOPMENTS</i>	125
MERCK & CO.	125

<b>TOPIC</b>	<b>PAGE NO.</b>
FINANCIALS	125
<i>TABLE 61 MERCK &amp; CO. REVENUES AND R &amp; D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)</i>	126
DEVELOPMENTS	126
<i>TABLE 62 MERCK &amp; CO. DEVELOPMENTS</i>	126
PFIZER	126
FINANCIALS	127
<i>TABLE 63 PFIZER REVENUES AND R &amp; D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)</i>	127
DEVELOPMENTS	127
<i>TABLE 64 PFIZER DEVELOPMENTS</i>	127
RECENT MERGERS AND ACQUISITIONS	128
<i>TABLE 65 LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET</i>	129
CHAPTER 8 CLINICAL TRIALS ON ANTIBIOTICS	133
<i>FIGURE 9 ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2015 (%)</i>	134
<i>TABLE 66 ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2015</i>	135
ANTIBIOTICS IN PHASE II CLINICAL TRIALS	136
<i>TABLE 67 ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2015</i>	136
ANTIBIOTICS IN PHASE I CLINICAL TRIALS	137
<i>TABLE 68 ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2015</i>	138
<i>TABLE 69 NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY THAT REPRESENT NEW CHEMICAL CLASSES, 2015</i>	139
CHAPTER 9 OVERVIEW OF BACTERIA TYPES	142
DISEASE ORGANISMS, DIAGNOSTICS, CLINICAL MANIFESTATIONS AND TREATMENTS	142
<i>TABLE 70 LIST OF GRAM-POSITIVE BACTERIA</i>	142
<i>TABLE 71 LIST OF GRAM-NEGATIVE BACTERIA</i>	146
<i>TABLE 72 LIST OF GRAM-NEGATIVE COCCI</i>	151
<i>TABLE 73 LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS</i>	153
<i>TABLE 74 LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT</i>	155
<i>TABLE 75 LIST OF GRAM-NEGATIVE SPIROCHETES</i>	159
<i>TABLE 76 LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES</i>	161
<i>TABLE 77 LIST OF MISCELLANEOUS BACTERIA</i>	163
CHAPTER 10 LIST OF ACRONYMS	166
LIST OF ACRONYMS	166



**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 (\$ MILLIONS)	8
TABLE 1 DIFFERENCES BETWEEN GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA	11
TABLE 2 CLASSIFICATION OF BACTERIA BY SHAPE	13
TABLE 3 PRINCIPLES FOR JUDICIAL USE OF ANTIBIOTICS	15
TABLE 4 INCIDENCE OF UPPER RESPIRATORY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)	17
TABLE 5 COMMON CAUSATIVE MICROBES OF COMMUNITY AND HOSPITAL-ACQUIRED PNEUMONIA	18
TABLE 6 PREFERRED PHARMACOTHERAPY FOR MICROORGANISMS CAUSING BACTERIAL PNEUMONIA	19
TABLE 7 INCIDENCE OF COMMUNITY-ACQUIRED PNEUMONIA BY COUNTRY, 2010 (NUMBER/%)	19
TABLE 8 INCIDENCE OF URINARY TRACT INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)	21
TABLE 9 INCIDENCE OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)	22
TABLE 10 INCIDENCE OF BACTERIAL VAGINOSIS INFECTIONS CAUSED BY STREPTOCOCCUS BY COUNTRY, 2010 (NUMBER/%)	24
TABLE 11 U.S. LIFE EXPECTANCY AT BIRTH, 1920-2013 (YEARS)	26
TABLE 12 ANTIBIOTICS: YEAR OF INTRODUCTION, MODE OF ACTION AND TARGET SPECIES	27
TABLE 13 ANTIBIOTICS: MODE OF ACTION	30
TABLE 14 ESTIMATED DEATHS PER YEAR CAUSED BY AMR BY REGION, 2050 (NUMBER)	31
TABLE 15 TYPES OF ANTIBIOTICS AND METHODS OF RESISTANCE	34
TABLE 16 CURRENT AND EMERGING ANTIBIOTIC-RESISTANT BACTERIA	35
TABLE 17 BIOCHEMICAL MECHANISM OF ANTIBIOTIC RESISTANCE	37
TABLE 18 ADDITIONAL COST AND LENGTH OF STAY DUE TO ANTIBIOTIC-RESISTANT BACTERIA BY REGION	38
TABLE 19 COMPARISON OF U.S. AND EU ORPHAN DRUG LEGISLATION AND PROCESS	73
TABLE 20 LIST OF DELINKAGE MODELS	75
TABLE 21 LIST OF HYBRID MODELS	77
TABLE 22 GLOBAL ANTIBIOTICS MARKET BY CLASS, THROUGH 2020 (\$ MILLIONS)	81
TABLE 23 GLOBAL ANTIBIOTICS MARKET BY REGION, THROUGH 2020 (\$ MILLIONS)	81
TABLE 24 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY TYPE, THROUGH 2020 (\$ MILLIONS)	84
TABLE 25 GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS BY REGION, THROUGH 2020 (\$ MILLIONS)	84
TABLE 26 GLOBAL MARKET FOR PENICILLIN BY REGION, THROUGH 2020 (\$ MILLIONS)	86
TABLE 27 TYPES OF PENICILLIN BY BRAND NAME AND APPROVAL DATE	88
TABLE 28 GLOBAL MARKET FOR CEPHALOSPORIN BY REGION, THROUGH 2020 (\$ MILLIONS)	89
TABLE 29 GENERATIONS OF CEPHALOSPORIN	90
TABLE 30 LIST OF FIRST-GENERATION CEPHALOSPORINS	91
TABLE 31 LIST OF SECOND-GENERATION CEPHALOSPORINS	92
TABLE 32 LIST OF THIRD-GENERATION CEPHALOSPORINS	93
TABLE 33 LIST OF FOURTH-GENERATION CEPHALOSPORINS	94

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 34 LIST OF FIFTH-GENERATION CEPHALOSPORINS	95
TABLE 35 GLOBAL MARKET FOR CARBAPENEM BY REGION, THROUGH 2020 (\$ MILLIONS)	96
TABLE 36 TYPES OF CARBAPENEMS	96
TABLE 37 DEVELOPMENT HISTORY OF FLUOROQUINOLONES	98
TABLE 38 GLOBAL MARKET FOR FLUOROQUINOLONES BY GENERATION, THROUGH 2020 (\$ MILLIONS)	98
TABLE 39 GLOBAL MARKET FOR FLUOROQUINOLONES BY REGION, THROUGH 2020 (\$ MILLIONS)	99
TABLE 40 GLOBAL MARKET FOR SECOND-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 (\$ MILLIONS)	100
TABLE 41 GLOBAL MARKET FOR THIRD-GENERATION FLUOROQUINOLONES BY REGION, THROUGH 2020 (\$ MILLIONS)	101
TABLE 42 GLOBAL MARKET FOR OTHER QUINOLONES BY REGION, THROUGH 2020 (\$ MILLIONS)	102
TABLE 43 TYPES OF QUINOLONES	102
TABLE 44 GLOBAL MARKET FOR TETRACYCLINE BY REGION, THROUGH 2020 (\$ MILLIONS)	104
TABLE 45 TYPES OF TETRACYCLINE	104
TABLE 46 GLOBAL MARKET FOR MACROLIDE BY REGION, THROUGH 2020 (\$ MILLIONS)	106
TABLE 47 TYPES OF MACROLIDES/KETOLIDES	107
TABLE 48 GLOBAL MARKET FOR OTHER ANTIBIOTICS BY REGION, THROUGH 2020 (\$ MILLIONS)	108
TABLE 49 DIFFERENCES BETWEEN ANTIBIOTIC USAGE IN ANIMALS AND HUMANS	111
TABLE 50 GLOBAL MARKET FOR VETERINARY ANTIBIOTICS BY APPLICATION, THROUGH 2020 (\$ MILLIONS)	112
TABLE 51 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY TYPE, THROUGH 2020 (\$ MILLIONS)	114
TABLE 52 GLOBAL MARKET FOR VETERINARY THERAPEUTIC ANTIBIOTICS BY ANIMAL TYPE, THROUGH 2020 (\$ MILLIONS)	115
TABLE 53 ASTRAZENECA REVENUES AND R & D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)	118
TABLE 54 ASTRAZENECA DEVELOPMENTS	119
TABLE 55 BAYER REVENUES AND R & D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)	120
TABLE 56 CUBIST PHARMACEUTICAL DEVELOPMENTS	121
TABLE 57 GSK REVENUES AND R & D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)	122
TABLE 58 GSK DEVELOPMENTS	123
TABLE 59 JOHNSON & JOHNSON REVENUES AND R & D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)	124
TABLE 60 JOHNSON & JOHNSON DEVELOPMENTS	125
TABLE 61 MERCK & CO. REVENUES AND R & D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)	126
TABLE 62 MERCK & CO. DEVELOPMENTS	126
TABLE 63 PFIZER REVENUES AND R & D EXPENDITURES, 2012-2014 (\$ MILLIONS/%)	127
TABLE 64 PFIZER DEVELOPMENTS	127
TABLE 65 LIST OF OTHER COMPANIES IN THE ANTIBIOTICS MARKET	129
TABLE 66 ANTIBIOTIC COMPOUNDS IN PHASE III CLINICAL TRIALS, 2015	135
TABLE 67 ANTIBIOTIC COMPOUNDS IN PHASE II CLINICAL TRIALS, 2015	136
TABLE 68 ANTIBIOTIC COMPOUNDS IN PHASE I CLINICAL TRIALS, 2015	138

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 69 NATURAL PRODUCTS IN CLINICAL TRIALS FOR ANTIBIOTIC ACTIVITY THAT REPRESENT NEW CHEMICAL CLASSES, 2015	139
TABLE 70 LIST OF GRAM-POSITIVE BACTERIA	142
TABLE 71 LIST OF GRAM-NEGATIVE BACTERIA	146
TABLE 72 LIST OF GRAM-NEGATIVE COCCI	151
TABLE 73 LIST OF GRAM-NEGATIVE RODS RELATED TO RESPIRATORY TRACT INFECTIONS	153
TABLE 74 LIST OF GRAM-NEGATIVE RODS RELATED TO THE ENTERIC TRACT	155
TABLE 75 LIST OF GRAM-NEGATIVE SPIROCHETES	159
TABLE 76 LIST OF GRAM-NEGATIVE OBLIGATE INTRACELLULAR PARASITES	161
TABLE 77 LIST OF MISCELLANEOUS BACTERIA	163

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL ANTIBIOTICS MARKET BY CLASS, 2015 AND 2020 (\$ MILLIONS)	8
FIGURE 1 CLASSIFICATION OF ANTIBIOTICS	25
FIGURE 2 CDC LIST OF HIGHLY CONCERNING BACTERIA, ACCORDING TO THREAT LEVEL	37
FIGURE 3 INCREASE IN AGING POPULATION, 2011 AND 2050	41
FIGURE 4 GLOBAL MARKET SHARES FOR ANTIBIOTIC COMPANIES, 2014 (%)	46
FIGURE 5 REASONS FOR LACK OF INNOVATION IN ANTIBIOTIC RESEARCH	60
FIGURE 6 STRATEGIES TO PROMOTE ANTIBIOTIC RESEARCH	62
FIGURE 7 ANTIBIOTICS BY CLASS	81
FIGURE 8 TYPES OF BETA-LACTAM ANTIBIOTICS	85
FIGURE 9 ANTIBIOTICS IN PHASES I-III CLINICAL TRIALS, 2015 (%)	134